Sam Brusco, Associate Editor10.11.22
Orthofix will present long-term evidence highlighting cervical disc arthroplasty clinical management at this year’s North American Spine Society (NASS) annual meeting.
The presentation will be conducted on Wednesday, Oct. 12 at 12:00 pm in the Red Theater located in the Exhibit Hall by Dr. Armen Khachatryan, Dr. Frank Phillips, Dr. Josh Jacobs, Steve Kurtz, Ph.D., and Gunnar Andersson, Ph.D.
“We are pleased to sponsor the presentation of data supporting the clinical effectiveness of cervical disc arthroplasty including five-year data from our U.S. IDE study,” Kevin Kenny, global president of Orthofix Spine told the press. “We are honored to have a distinguished surgeon panel that will provide their insights about cervical disc replacement and long-term outcomes of this therapy for patients suffering from degenerative disc disease.”
Recently released IDE study data showed significant benefits at five years compared to anterior cervical discectomy and fusion (ACDF), including reduction in disability, reduction in shoulder/arm pain, and one of the lowest subsequent surgical intervention rates (3.1%) compared other FDA-approved aerificial cervical discs.
Orthofix’s M6 artificial cervical disc aims to maintain natural functional spinal unit behavior by replicating the native disc’s biomechanical characteristics. The disc received FDA approval in 2019 and to date over 70,000 M6-C discs have been implanted in over 20 countries.
The presentation will be conducted on Wednesday, Oct. 12 at 12:00 pm in the Red Theater located in the Exhibit Hall by Dr. Armen Khachatryan, Dr. Frank Phillips, Dr. Josh Jacobs, Steve Kurtz, Ph.D., and Gunnar Andersson, Ph.D.
“We are pleased to sponsor the presentation of data supporting the clinical effectiveness of cervical disc arthroplasty including five-year data from our U.S. IDE study,” Kevin Kenny, global president of Orthofix Spine told the press. “We are honored to have a distinguished surgeon panel that will provide their insights about cervical disc replacement and long-term outcomes of this therapy for patients suffering from degenerative disc disease.”
Recently released IDE study data showed significant benefits at five years compared to anterior cervical discectomy and fusion (ACDF), including reduction in disability, reduction in shoulder/arm pain, and one of the lowest subsequent surgical intervention rates (3.1%) compared other FDA-approved aerificial cervical discs.
Orthofix’s M6 artificial cervical disc aims to maintain natural functional spinal unit behavior by replicating the native disc’s biomechanical characteristics. The disc received FDA approval in 2019 and to date over 70,000 M6-C discs have been implanted in over 20 countries.